Topics

Articles

Blue Fin Group exec speaks on his upcoming feature. 

SVP and Managing Director for Blue Fin Group offers a synopsis of the conference opener. 

Director of Berkeley Research Group explains changes to 340B moving forward. 

Berkeley Research Group executive speaks about the role of manufacturers in 340B pricing. 

Berkeley Research Group Director discusses what to expect at his upcoming session. 

Tirzepatide (Zepbound; Eli Lilly and Company) will hit the US market by the end of 2023 with a list price of $1,059.87.

Study describes how biotech startups can avoid competing with large pharma companies for financing. 

HDA research reveals that 95% of pharma transactions move through the traditional distribution channel. 

Payers won’t let these products break the bank.

The conference will focus on the full breadth of commercialization strategies and operations. 